+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating CYB003, a deuterated psilocin analog, as an additional treatment for adults with Major Depressive Disorder MDD. This Phase III study aims to assess the effectiveness, safety, and tolerability of two different doses of CYB003 compared to a placebo in people who continue their current antidepressant medication. The study is randomized, double-blind, and involves multiple centers. Participants are assigned to one of three groups two experimental arms receiving either 8 mg or 16 mg of CYB003 during two medicine sessions spaced about three weeks apart, or a placebo arm receiving placebo sessions on the same schedule. Throughout the trial, all participants maintain their current antidepressants and receive psychological support. Non-responders to placebo may join a later extension trial to receive CYB003. During the trial, participants undergo evaluations using several scales that assess depression severity, anxiety, global clinical impression, and quality of life at multiple time points from screening through up to 84 days or end of trial. Psychological support sessions and dosing visits are conducted, and safety is monitored. The total study participation lasts approximately three months, with detailed assessments scheduled at baseline and various days post-treatment.

Age: 18Years - 85YearsAll GendersPhase 3
79 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TSND-201 in adults diagnosed with Post Traumatic Stress Disorder PTSD. This Phase 3 trial is designed to test how well TSND-201 works compared to a placebo in treating PTSD symptoms. Eligible participants must have a current diagnosis of PTSD lasting at least six months and have tried previous treatments such as medication or trauma-focused psychotherapy. Participants will be randomly assigned to one of three groups two different doses of TSND-201 or a placebo. Each participant will take capsules orally once a week for four consecutive weeks during the Treatment Period. After completing treatment, participants will enter an 8-week Follow-up Period to monitor their progress without additional treatment. Throughout the study, participants will be assessed using the Clinician-Administered PTSD Scale for DSM-5 CAPS-5 to measure changes in PTSD symptom severity from baseline up to 12 weeks. Regular interviews and questionnaires will be completed to track safety and efficacy. The study aims to complete by December 2027, with careful monitoring to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
37 locations